Nurix Therapeutics Inc

Nurix Therapeutics Inc

NRIX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.69B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Nurix Therapeutics IncNurix Therapeutics Inc6.2-30%2.60.1
$33.80

Target Price by Analysts

118.3% upsideNurix Therapeutics Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.69 Billion
Enterprise Value$1.04 Billion
Earnings per Share$-3.05
Beta1.8
Outstanding Shares111,563,067

Return

Return on Equity30.45%ROE
Return on Assets24.67%
Return on Invested Capital28.45%

Valuation & Multiples

P/E Ratio6.17P/E Ratio
PEG-0.84PEG
Price to Sales2.58Price to Sales
Price to Book Ratio1.94Price to Book Ratio
Enterprise Value to Revenue1.49
Enterprise Value to EBIT3.45
Enterprise Value to Net Income3
Total Debt to Enterprise0.07
Debt to Equity0.08Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 12, 2026
EPS
$4.73
Est. -$0.60
Revenue
$673.06 M
Est. $24.35 M

Next Earnings Call

Expected Date
January 27, 2027
EPS Estimate
-$0.46
Consensus analyst estimate
Revenue Estimate
$287.86 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 32.69%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %8.06%▼ 98.25%
Total Invested$212.30M▼ 92.59%
Investors Holding67▼ 151.00%

About Nurix Therapeutics Inc

2,020 employees

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...

Nurix Therapeutics Insider Information FAQ

Stockcircle tracks 5 top investors with a current 13F position in Nurix Therapeutics. Notable holders include ARK Invest. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions and 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 20 open-market insider sales for Nurix Therapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.